IMATINIB ARISTO 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

imatinib aristo 400 mg comprimidos recubiertos con pelicula efg

aristo pharma gmbh - imatinib mesilato - comprimido recubierto con pelÍcula - 400 mg - imatinib mesilato 400 mg - imatinib

Imatinib Koanaa Unión Europea - español - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - agentes antineoplásicos - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. los pacientes que tienen un riesgo bajo o muy bajo de recurrencia no debe recibir tratamiento adyuvante. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. excepto en recién diagnosticados de lmc en fase crónica, no existen ensayos controlados que demuestran un beneficio clínico o el aumento de la supervivencia para estas enfermedades.

IMATINIB DR REDDYS 100 MG CAPSULAS DURAS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

imatinib dr reddys 100 mg capsulas duras efg

reddy pharma iberia s.a. - imatinib mesilato - cÁpsula dura - 100 mg - imatinib mesilato 100 mg - imatinib

IMATINIB DR REDDYS 400 MG CAPSULAS DURAS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

imatinib dr reddys 400 mg capsulas duras efg

reddy pharma iberia s.a. - imatinib mesilato - cÁpsula dura - 400 mg - imatinib mesilato 400 mg - imatinib

IMATINIB TORREFARMA 100 MG CAPSULAS DURAS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

imatinib torrefarma 100 mg capsulas duras efg

torrefarma, s.l. - imatinib mesilato - cÁpsula dura - 100 mg - imatinib mesilato 100 mg - imatinib

IMATINIB TARBIS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

imatinib tarbis 100 mg comprimidos recubiertos con pelicula efg

tarbis farma s.l. - imatinib mesilato - comprimido recubierto con pelÍcula - 100 mg - imatinib mesilato 100 mg - imatinib

IMATINIB TARBIS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

imatinib tarbis 400 mg comprimidos recubiertos con pelicula efg

tarbis farma s.l. - imatinib mesilato - comprimido recubierto con pelÍcula - 400 mg - imatinib mesilato 400 mg - imatinib

IMATIB 400 400 mg TABLETA RECUBIERTA Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

imatib 400 400 mg tableta recubierta

seven pharma s.a.c. - droguerÍa - mesilato de imatinib; - tableta recubierta - por tableta - - imatinib

IMALEK 100 mgTABLETAS RECUBIERTAS Venezuela - español - Instituto Nacional de Higiene

imalek 100 mgtabletas recubiertas

regifarm, s.r.l. - imatinib - tableta - 100 mg

IMALEK 400 mg TABLETAS RECUBIERTAS Venezuela - español - Instituto Nacional de Higiene

imalek 400 mg tabletas recubiertas

regifarm, s.r.l. - imatinib - tabletas recubiertas - 400 mg